From: Further-line treatment
Copyright © NICE 2022.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Further-line treatment: Depression in adults: Evidence review D. London: National Institute for Health and Care Excellence (NICE); 2022 Jun. (NICE Guideline, No. 222.)
Further-line treatment: Depression in adults: Evidence review D.
Show detailsTable 50Summary of included studies. Comparison 49. Augmenting with antipsychotic versus switch to bupropion
| Study | Population | Intervention | Comparison | Details of inadequate response/treatment resistance | Comments |
|---|---|---|---|---|---|
|
RCT US |
N=1016 Mean age (years): 54.4 Gender (% female): 14 Ethnicity (% BME): 32 Baseline severity: QIDS 16.75 (more severe) | Aripiprazole 2-15mg/day + SSRI/SNRI | Bupropion monotherapy 150-400mg/day | Inadequate response (QIDS score ≥16 after ≥6 weeks of treatment or score≥11 after ≥8 weeks of treatment with the 3 most recent weeks at a stable “optimal” dose) to a treatment course with a SSRI, SNRI, or mirtazapine that met or exceeded minimal standards for dose and duration of treatment |
Treatment length (weeks): 12 Outcomes:
|
BME: black and minority ethnic; QIDS: quick inventory of depressive symptomatology; RCT: randomised controlled trial; SNRI: serotonin-norepinephrine reuptake inhibitor; SSRI: selective serotonin reuptake inhibitor
- Review The Black Book of Psychotropic Dosing and Monitoring.[Psychopharmacol Bull. 2024]Review The Black Book of Psychotropic Dosing and Monitoring.DeBattista C, Schatzberg AF. Psychopharmacol Bull. 2024 Jul 8; 54(3):8-59.
- A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don't work well enough?[World J Biol Psychiatry. 2021]A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don't work well enough?Dodd S, Bauer M, Carvalho AF, Eyre H, Fava M, Kasper S, Kennedy SH, Khoo JP, Lopez Jaramillo C, Malhi GS, et al. World J Biol Psychiatry. 2021 Sep; 22(7):483-494. Epub 2020 Dec 8.
- Pharmacologic approaches to treatment resistant depression: Evidences and personal experience.[World J Psychiatry. 2015]Pharmacologic approaches to treatment resistant depression: Evidences and personal experience.Tundo A, de Filippis R, Proietti L. World J Psychiatry. 2015 Sep 22; 5(3):330-41.
- Review [Antipsychotics in bipolar disorders].[Encephale. 2004]Review [Antipsychotics in bipolar disorders].Vacheron-Trystram MN, Braitman A, Cheref S, Auffray L. Encephale. 2004 Sep-Oct; 30(5):417-24.
- The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.[J Clin Psychiatry. 2003]The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.Kane JM, Leucht S, Carpenter D, Docherty JP, Expert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic Disorders. J Clin Psychiatry. 2003; 64 Suppl 12:5-19.
- Table 50, Summary of included studies. Comparison 49. Augmenting with antipsycho...Table 50, Summary of included studies. Comparison 49. Augmenting with antipsychotic versus switch to bupropion - Further-line treatment
- Thesium annulatum[All Fields] (0)MedGen
- Rhynchostegium lepidopilum (0)Nucleotide
- (E) AND -9-Bromonon-5-en-3-yne (0)Conserved Domains
- Thorncroftia[orgn] (0)Structure
Your browsing activity is empty.
Activity recording is turned off.
See more...